A STUDY OF PHARMACOKINETIC DRUG INTERACTION STUDY OF THE HEDGEHOG PATHWAY INHIBITOR GDC-0449 IN COMBINATION WITH ROSIGLITAZONE OR COMBINED ORAL CONTRACEPTIVE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT ARE REFRACTORY TO STANDARD THERAPY OR FOR WHOM NO STANDARD THERAPY EXISTS: